GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Ending Cash Position

SRZN (Surrozen) Ending Cash Position : $31.70 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Surrozen Ending Cash Position?

Surrozen's Ending Cash Position for the quarter that ended in Sep. 2024 was $31.70 Mil.

Surrozen's quarterly Ending Cash Position increased from Mar. 2024 ($27.98 Mil) to Jun. 2024 ($38.45 Mil) but then declined from Jun. 2024 ($38.45 Mil) to Sep. 2024 ($31.70 Mil).

Surrozen's annual Ending Cash Position declined from Dec. 2021 ($33.50 Mil) to Dec. 2022 ($25.10 Mil) but then increased from Dec. 2022 ($25.10 Mil) to Dec. 2023 ($36.73 Mil).

Surrozen Ending Cash Position Historical Data

The historical data trend for Surrozen's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surrozen Ending Cash Position Chart

Surrozen Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Ending Cash Position
35.39 33.50 25.10 36.73

Surrozen Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.40 36.73 27.98 38.45 31.70

Surrozen Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Surrozen's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=25.095+11.636
=36.73

Surrozen's Ending Cash Position for the quarter that ended in Sep. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=38.453+-6.753
=31.70

Surrozen Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Surrozen's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Surrozen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Surrozen Inc (NAS:SRZN) » Definitions » Ending Cash Position
Comparable Companies
HRGN XLO ESLA OMGA ICCC CASI GANX VYNE RANI ANTX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
Website
https://www.surrozen.com
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Executives
Tim Kutzkey director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Anna Berkenblit director 830 WINTER STREET, WALTHAM MA 02451
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Blutt Mitchell J Md director, 10 percent owner 1370 AVENUE OF THE AMERICA, SUITE 3301, NEW YORK NY 10019
Christopher Y Chai director 2400 BAYSHORE PARKWAY, SUITE 200, MOUNTAIN VIEW CA 94043
Mary Haak-frendscho director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Wen-chen Yeh officer: Chief Scientific Officer 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
House Joshua Cory other: Former VP Business Development C/O CONSONANCE-HWF ACQUISITION CORP, 1 PALMER SQUARE, SUITE 305, PRINCETON NJ 08540
Geertrui Vanhove officer: Chief Medical Officer 1333 S. SPECTRUM BLVD #100, CHANDLER AZ 85286
Charles O Williams officer: Chief Financial Officer C/O HERITAGE FINANCIAL GROUP, 721 NORTH WESTOVER BOULEVARD, ALBANY GA 31707
Mace Rothenberg director 171 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Donald J Santel other: Former Director 4362 24TH STREET, SAN FRANCISCO CA 94114
David J Woodhouse director 630 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158